Moxi Strong - Moxidectin for Strongyloidiasis

The overarching goal of this project is to assemble for the first time key data on the safety and efficacy and pharmacokinetics of moxidectin for the treatment of strongyloidiasis. We propose to conduct a Phase 2a  The project consists of three objectives:
1. What is the efficacy and safety of ascending moxidectin doses (2-12 mg versus placebo) against S. stercoralis infections in adults?
2. Can dried blood spots be used to analyse pharmacokinetic (PK) properties of moxidectin?
3. What are the key PK parameters of moxidectin in patients infected with S. stercoralis?

Contact

Jennifer Keiser

Jennifer Keiser, Associate Professor, PhD
Head of Unit

+41612848218
jennifer.keiserswisstph.ch

Project Facts

Collaborating Institutions